Sana Biotechnology, Inc.
NASDAQSana Biotechnology heads into its August 11 earnings print as one of the most heavily shorted small-cap biotechs in the gene-therapy space, with the stock's brief recovery doing little to shake a persistently bearish positioning structure. Short sellers have not blinked. Short interest holds at 15.2% of the free float — roughly 40.4 million shares — and has crept higher over the…
Snapshot as of 24 Sept 2026
Sana Biotechnology heads into its August 11 earnings print as one of the most heavily shorted small-cap biotechs in the gene-therapy space, with the stock's brief recovery doing little to shake a persistently bearish…
Sana Biotechnology enters the second half of 2026 with a tightening contradiction: short sellers are quietly adding exposure while options traders have turned more bullish than at almost any point in the past year. The…
SANA enters its May 14 earnings report carrying one of the most crowded short books in its sector — and the bears have not blinked. Short interest runs at 14.5% of the free float, a level that places the stock in the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SANA — free to start on ORTEX.
Sign up for free →Open SANA on ORTEX